GlassScriptPhysician profile
Jakob Probst
NPI 1386267243
$1,174.19
in general payments reported to CMS, 2019-2025
15 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2.67 · 2023: $99.11 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.03 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $287.58 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $169.83 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.06 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $136.19 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $118.04 | 2025 | |
| Lundbeck LLC | $74.48 | 2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $74.16 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $50.87 | 2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $30.74 | 2025 | Sublocade |
| Tris Pharma INC | $24.04 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $17.76 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $14.99 | 2025 | Fanapt |
| Noven Therapeutics, LLC | $14.22 | 2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $13.56 | 2025 | Trintellix |
| Genentech USA, INC. | $2.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jakob Probst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.